Bortezomib activates the stress kinase JNK and the c-Jun/AP-1 signal pathway, thus inducing the expression of the cyclin-CDK inhibitor p21, leading to growth arrest and apoptosis of NSCLC cells [52]. The gene discussed is JUN; the disease is non-small cell lung carcinoma.